Stock Scorecard



Stock Summary for Context Therapeutics Inc (CNTX) - $0.66 as of 6/30/2025 9:05:13 PM EST

Total Score

13 out of 30

Safety Score

26 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CNTX

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CNTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CNTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CNTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CNTX (26 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for CNTX

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting 6/2/2025 11:30:00 AM
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - Context Therapeutics ( NASDAQ:CNTX ) 5/29/2025 11:30:00 AM
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer 5/29/2025 11:30:00 AM
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 5/12/2025 8:38:00 PM
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting - Context Therapeutics ( NASDAQ:CNTX ) 4/30/2025 11:30:00 AM
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting 4/30/2025 11:30:00 AM
Bet on These 5 Top-Ranked Stocks With Rising P/E 4/21/2025 11:40:00 AM
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 4/9/2025 11:30:00 AM
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains 4/3/2025 12:11:00 PM
Context Therapeutics to Participate in Upcoming Investor Conferences - Context Therapeutics ( NASDAQ:CNTX ) 4/1/2025 11:30:00 AM

Financial Details for CNTX

Company Overview

Ticker CNTX
Company Name Context Therapeutics Inc
Country USA
Description Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of chronic pain. The company is headquartered in Boston, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 0.66
Price 4 Years Ago 2.66
Last Day Price Updated 6/30/2025 9:05:13 PM EST
Last Day Volume 161,470
Average Daily Volume 306,147
52-Week High 2.75
52-Week Low 0.49
Last Price to 52 Week Low 34.69%

Valuation Measures

Trailing PE N/A
Industry PE 22.52
Sector PE 40.73
5-Year Average PE -3.60
Free Cash Flow Ratio 0.66
Industry Free Cash Flow Ratio 17.94
Sector Free Cash Flow Ratio 32.54
Current Ratio Most Recent Quarter 48.80
Total Cash Per Share 1.00
Book Value Per Share Most Recent Quarter 1.01
Price to Book Ratio 0.64
Industry Price to Book Ratio 35.01
Sector Price to Book Ratio 30.79
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 123.25
Sector Price to Sales Ratio Twelve Trailing Months 35.57
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 89,704,000
Market Capitalization 59,204,640
Institutional Ownership 79.93%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -11.52%
Reported EPS 12 Trailing Months -0.28
Reported EPS Past Year -0.05
Reported EPS Prior Year -0.53
Net Income Twelve Trailing Months -27,635,000
Net Income Past Year -26,725,000
Net Income Prior Year -23,964,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 335.62%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 89,352,227
Total Cash Past Year 94,429,824
Total Cash Prior Year 14,449,827
Net Cash Position Most Recent Quarter 89,352,227
Net Cash Position Past Year 94,429,824
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 95,266,262
Total Stockholder Equity Prior Year 11,871,020
Total Stockholder Equity Most Recent Quarter 90,982,718

Free Cash Flow

Free Cash Flow Twelve Trailing Months -15,265,981
Free Cash Flow Per Share Twelve Trailing Months -0.17
Free Cash Flow Past Year -29,313,000
Free Cash Flow Prior Year -21,047,618

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.03
MACD Signal -0.03
20-Day Bollinger Lower Band 0.52
20-Day Bollinger Middle Band 0.73
20-Day Bollinger Upper Band 0.94
Beta 1.86
RSI 49.16
50-Day SMA 1.23
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 6/30/2025 9:05:16 PM EST